Lipocine Stock Analysis

LPCN -  USA Stock  

USD 1.01  0.04  3.81%

The latest Lipocine price slide may encourage institutional investors to take a closer look at the firm as it is trading at a share price of 1.01 on 599,900 in trading volume. The company directors and management were unable to exploit market volatilities in November. However, diversifying your overall positions with Lipocine can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.19. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Lipocine partners.
Additionally, see Stocks Correlation.

Lipocine Stock Analysis 

 
Refresh
The Lipocine stock analysis report makes it easy to digest most publicly released information about Lipocine and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Lipocine Stock analysis module also helps to analyze the Lipocine price relationship with some important fundamental indicators such as market cap and management efficiency.

Lipocine Stock Analysis Notes

The book value of the company was now reported as 0.48. The company recorded a loss per share of 0.28. Lipocine had not issued any dividends in recent years. The entity had 1:100 split on the 25th of July 2013. Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. The companys pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. Lipocine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. To find out more about Lipocine contact Mahesh Patel at 801 994 7383 or learn more at http://www.lipocine.com.

Lipocine Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Lipocine's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Lipocine or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Lipocine generated a negative expected return over the last 90 days
Lipocine has some characteristics of a very speculative penny stock
Lipocine has high historical volatility and very poor performance
Net Loss for the year was (19 M) with loss before overhead, payroll, taxes, and interest of (5.05 M).
Lipocine currently holds about 46.64 M in cash with (14.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53.
Lipocine has a frail financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Purchase by Mahesh Patel of 25000 shares of Lipocine

Lipocine Upcoming and Recent Events

Earnings reports are used by Lipocine to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lipocine previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report10th of March 2022
Next Earnings Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End10th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Lipocine Largest EPS Surprises

Earnings surprises can significantly impact Lipocine's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-05-06
2021-03-31-0.05-0.040.0120 
2020-11-10
2020-09-30-0.06-0.07-0.0116 
2021-11-10
2021-09-30-0.0425-0.030.012529 
View All Earnings Estimates

Lipocine SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Lipocine prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Lipocine investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Lipocine specific information freely available to individual and institutional investors to make a timely investment decision.
10th of November 2021
Financial Statements and Exhibits. Other Events
View
9th of November 2021
Financial Statements and Exhibits. Other Events
View
4th of November 2021
Financial Statements and Exhibits. Other Events
View
1st of November 2021
Financial Statements and Exhibits. Other Events. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year. Material Modifications to Rights of Security Holders. Entry into a Material Definitive Agreement
View
18th of October 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Entry into a Material Definitive Agreement
View
12th of October 2021
Financial Statements and Exhibits. Other Events
View
28th of September 2021
Financial Statements and Exhibits. Other Events
View
13th of September 2021
Financial Statements and Exhibits. Other Events
View

Lipocine Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Lipocine is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lipocine backward and forwards among themselves. Lipocine's institutional investor refers to the entity that pools money to purchase Lipocine's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vanguard Group IncCommon Shares3.8 M4.2 M
Blackrock IncCommon Shares1.6 M1.7 M
Geode Capital Management LlcCommon Shares824.4 K898 K
Group One Trading LpCall Options625.5 K682 K
Morgan StanleyCommon Shares421.2 K459 K
Ameriprise Financial IncCommon Shares406 K443 K
Gsa Capital Partners LlpCommon Shares315.3 K344 K
Mercer Global Advisors IncCommon Shares313.1 K341 K
Simplex Trading LlcPut Options75.8 K106 K
Note, although Lipocine's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Lipocine Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 90.06 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Lipocine's market, we take the total number of its shares issued and multiply it by Lipocine's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Lipocine Profitablity

Lipocine's profitability indicators refer to fundamental financial ratios that showcase Lipocine's ability to generate income relative to its revenue or operating costs. If, let's say, Lipocine is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Lipocine's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Lipocine's profitability requires more research than a typical breakdown of Lipocine's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Investment(89.56) (96.63) 
Return on Average Assets(0.89) (0.91) 
Return on Average Equity(1.70) (1.74) 
Return on Invested Capital(4.72) (5.10) 
Return on Sales(66.77) (68.53) 

Management Efficiency

The entity has return on total asset (ROA) of (27.03) % which means that it has lost $27.03 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (77.83) %, meaning that it created substantial loss on money invested by shareholders. Lipocine management efficiency ratios could be used to measure how well lipocine manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Investment is estimated to slide to -96.63. The value of Return on Average Assets is estimated to slide to -0.91. Lipocine Net Current Assets as percentage of Total Assets are quite stable at the moment as compared to the past year. The company's current value of Net Current Assets as percentage of Total Assets is estimated at 72.44. Asset Turnover is expected to rise to 0.007389 this year, although the value of Return on Average Assets will most likely fall to (0.91) .
Last ReportedProjected for 2021
Book Value per Share 0.28  0.28 
Enterprise Value over EBIT(4.60) (4.96) 
Enterprise Value over EBITDA(3.78) (4.08) 
Price to Book Value 5.82  5.02 
Tangible Assets Book Value per Share 0.46  0.47 
Enterprise Value77.8 M69.4 M
Tangible Asset Value25.4 M27.4 M

Technical Drivers

As of the 4th of December, Lipocine secures the risk adjusted performance of (0.08), and Mean Deviation of 2.5. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lipocine, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to break down nineteen technical drivers for Lipocine, which can be compared to its peers in the industry. Please verify Lipocine variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Lipocine is priced some-what accurately, providing market reflects its recent price of 1.01 per share. Given that Lipocine is a hitting penny stock territory we strongly suggest to closely look at its total risk alpha.

Lipocine Price Movement Analysis

The output start index for this execution was thirty with a total number of output elements of thirty-one. The Mid-point Price over period is an average of Lipocine highest and lowest prices attained during the given period. View also all equity analysis or get more info about midpoint price over period overlap studies indicator.

Lipocine Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lipocine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lipocine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lipocine insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Lipocine Predictive Daily Indicators

Lipocine intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lipocine stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Lipocine Forecast Models

Lipocine time-series forecasting models is one of many Lipocine's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lipocine's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Lipocine Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Lipocine stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Lipocine shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Lipocine. By using and applying Lipocine Stock analysis, traders can create a robust methodology for identifying Lipocine entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(66.69) (68.44) 
Gross Margin 0.90  0.89 
Profit Margin(70.95) (72.82) 
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. The companys pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. Lipocine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.

Current Lipocine Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Lipocine analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Lipocine analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
3.75Strong Buy4Odds
Lipocine current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Lipocine analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Lipocine stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Lipocine, talking to its executives and customers, or listening to Lipocine conference calls.
Lipocine Analyst Advice Details

Lipocine Stock Analysis Indicators

Lipocine stock analysis indicators help investors evaluate how Lipocine stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Lipocine shares will generate the highest return on investment. By understating and applying Lipocine stock analysis, traders can identify Lipocine position entry and exit signals to maximize returns.
Quick Ratio5.32
Fifty Two Week Low0.9810
Shares Short Prior Month3.5M
Average Daily Volume Last 10 Day586.99k
Average Daily Volume In Three Month656.87k
Shares Percent Shares Out4.19%
Short Percent Of Float4.29%
Forward Price Earnings5.37
Float Shares86.08M
Fifty Two Week High2.4200
Enterprise Value To Ebitda-4.44
Fifty Day Average1.1079
Two Hundred Day Average1.3298
Additionally, see Stocks Correlation. Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Lipocine Stock analysis

When running Lipocine price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Is Lipocine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine Lipocine value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.